Aubrey Rankin - 03 Dec 2021 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
President, Innovation & Tech, Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Dec 2021
Net transactions value
+$432,876
Form type
4
Filing time
06 Dec 2021, 19:34:29 UTC
Previous filing
17 Aug 2021
Next filing
17 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Purchase $432,876 +30,000 +46% $14.43 95,463 03 Dec 2021 Direct F1
holding RVNC Common Stock 154,302 03 Dec 2021 The Rankin Irrevocable Trust F2
holding RVNC Common Stock 321,611 03 Dec 2021 Aubrey and Luanne Rankin Revocable Living Trust Dated July 1, 2009 F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.33 to $14.50. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
F3 These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.